Dextroamphetamine extended-release (ER) is a medication used to treat attention deficit hyperactivity disorder (ADHD) [1]. It is a central nervous system stimulant [2].
How does Dextroamphetamine ER work?
Dextroamphetamine ER is believed to work by increasing the levels of certain neurotransmitters in the brain, primarily dopamine and norepinephrine [3]. These neurotransmitters play a role in attention, focus, and impulse control [4]. The extended-release formulation is designed to provide a more gradual release of the medication over time, leading to a longer duration of effect [5].
What is Dextroamphetamine ER prescribed for?
The primary indication for dextroamphetamine ER is the treatment of attention deficit hyperactivity disorder (ADHD) in both children and adults [1]. It helps to improve focus, reduce impulsivity, and decrease hyperactivity in individuals diagnosed with ADHD [4].
What are the different brand names for Dextroamphetamine ER?
Dextroamphetamine ER is available under several brand names, including Dexedrine Spansule and Zenzedi [6].
When does the patent for Dextroamphetamine ER expire?
Information regarding specific patent expiry dates for dextroamphetamine ER formulations can be found through specialized resources [7]. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can include details on when market exclusivity may end [7].
What are the potential side effects of Dextroamphetamine ER?
Common side effects of dextroamphetamine ER can include decreased appetite, dry mouth, weight loss, insomnia, and stomach pain [8]. More serious side effects may include cardiovascular issues such as increased blood pressure and heart rate, as well as psychiatric symptoms like anxiety or mood changes [8].
What are the risks associated with Dextroamphetamine ER?
As a stimulant medication, dextroamphetamine ER carries risks, including potential for abuse and dependence [9]. It is a Schedule II controlled substance due to this risk [9]. Cardiovascular risks, such as sudden death in individuals with pre-existing heart conditions, are also a concern [8].
How does Dextroamphetamine ER compare to other ADHD medications?
Dextroamphetamine ER is one of several stimulant medications used for ADHD. Other common stimulants include methylphenidate-based medications (e.g., Ritalin, Concerta) and amphetamine-based medications (e.g., Adderall) [10]. The choice of medication often depends on individual patient response, side effect profiles, and duration of action required [10]. Non-stimulant medications are also available for ADHD treatment [11].
Can I get Dextroamphetamine ER as a generic?
Yes, generic versions of dextroamphetamine extended-release capsules are available [6].
---
1. U.S. Food and Drug Administration. (n.d.). Dextroamphetamine Sulfate Extended Release Capsules. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/040051s047,040730s023,040774s015,204720s004lbl.pdf
2. National Institute on Drug Abuse. (2020, September). Stimulant ADHD Medications: What They Are and What They Do. Retrieved from https://nida.nih.gov/publications/research-reports/prescription-stimulants-adhd-medications/what-adhd-medications
3. American Academy of Child & Adolescent Psychiatry. (2019). ADHD Medications. Retrieved from https://www.aacap.org/AACAP/FamiliesandYouth/FactsforFamilies/FFF-19.aspx
4. Mayo Clinic. (2022, December 21). Attention deficit hyperactivity disorder (ADHD) in children. Retrieved from https://www.mayoclinic.org/diseases-conditions/adhd/symptoms-causes/syc-20350889
5. MedlinePlus. (2022, January 2). Dextroamphetamine and amphetamine. Retrieved from https://medlineplus.gov/druginfo/meds/a681020.html
6. GoodRx. (n.d.). Dextroamphetamine ER Side Effects, Uses, Dosage, Interactions. Retrieved from https://www.goodrx.com/dextroamphetamine-er
7. DrugPatentWatch.com. (n.d.). Dextroamphetamine ER Patent Information. Retrieved from https://drugpatentwatch.com/
8. WebMD. (n.d.). Dextroamphetamine ER Oral Uses, Side Effects, Dosage, Interactions. Retrieved from https://www.webmd.com/drugs/2/drug-16517/dextroamphetamine-er-oral/details
9. U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act - Schedule II. Retrieved from https://www.dea.gov/drug-scheduling
10. National Institute of Mental Health. (2021, July). Attention-Deficit/Hyperactivity Disorder. Retrieved from https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd
11. Cleveland Clinic. (n.d.). ADHD Medications. Retrieved from https://my.clevelandclinic.org/health/treatments/15174-adhd-medications